PRECEDE FOUNDATION INC

As filed

Subsection

03

Classification

1000

Street

250 MAMARONECK AVE UNIT 614

These codes are the IRS's own and are shown exactly as filed. What each one means is in the Business Master File documentation (opens in a new tab).

Mission and programs · 2025

• The PRECEDE Foundation supports the work being done by 65 academic medical centers around the world that are collaborating on early detection for pancreatic cancer.The Expenses associated with the program include operating a central data repository. PRECEDE Foundation contracts with an outside vendor that specializes in this activity - Arbor Research. Arbor is headquartered in Michigan and is reponsible for onboarding new medical centers, monitoring data completeness and quality,providing analytic support, managing the study IRB, and managing the data registry. Total 2025 expenses for Arbor Research were $605,407.The other major expense is for the Biospecimen repository which receives and stores blood samples for study participants who are part of industry sponsor studies seeking to validate new biomarker assays for pancreatic cancer. PRECEDE Foundation contracts with Azenta Life Sciences to function as the PRECEDE Biorespository. Total 2025 expenses for Azenta were $99,674.PRECEDE Foundation also supports the work being done at each medical center in support of the study. This includes the cost of a research coordinator at each site, the use of a genetic counselor to enroll, consent and screen participants and a data analyst to enter clinical and demographic data for each participant. Total payments to sites in 2025 were $124,170.To-Date program outcomes include:1) conducting a prospective, longitudial clinical validation study for ClearNote Health's early detection blood test - Avantect.2) working with Immunovia to design, devvelop and implement their clinical validation study for the PancreaSure test.3) working with BT Genomics/Singlera on the design of the clinical validation study for the BT Reveal Early Pancreatic Cancer test.4) we have already identified 42 cased of pancreatic ductal adenocarcinoma, 36 of which have early stage disease with an 87% 5-year survival rate. We have also detected 155 other cancers at various stages.5) we hosted an annual meeting with 175 of the principal investigators, other researchers and industry experts to exchange information, review progress, address new developments and design new areas of study to achieve the goal of early detection and a 50% survival rate for pancreatic cancer.

  Expenses $1,544,674

As filed on the 2025 return.

Officers and directors · 2025

As listed in Part VII of the 2025 return, in the order the filer printed them. Each return names its own; this is not a roster the organization keeps with us.

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us. Earlier years are each on their own filing page.

Filings

• 2025

  Revenue

  $2,062,871

  Expenses

  $1,886,658

  Contributions

  $1,378,810

  Grants paid

  $0

• 2024

  Revenue

  $1,245,897

  Expenses

  $1,571,647

  Contributions

  $1,133,212

  Grants paid

  $0

• 2023

  Revenue

  $1,388,468

  Expenses

  $519,137

  Contributions

  $140,864

  Grants paid

  $163,548

• 2022

  Revenue

  $143,231

  Expenses

  $160,173

  Contributions

  $139,381

  Grants paid

  $25,000

The four totals the IRS asks for on Part I of the Form 990, as filed. A dash means the figure was not present on the return — not that it was zero.

Other returns filed

• 2021 · 990

  Revenue

  $241,163

  Expenses

  $82,708

  Assets (EOY)

  $194,209

• 2020 · 990-EZ

  Revenue

  $42,028

  Expenses

  $6,274

  Assets (EOY)

  $35,754

Nonprofiteer parses Forms 990, 990-EZ and 990-PF, in a window of recent tax years. These returns are recorded from the IRS e-file index, so their figures were extracted by that index rather than read from the return here — treat them as a different source from the filings above, not as more of the same record. A dash means the index carries no figure; Form 990-T listings carry none at all.

Grants made

• ARBOR RESEARCH COLLABORATIVE

  $163,548

  2023 · CANCER RESEARCH

• ARBOR RESEARCH COLLABORATIVE FOR HE

  $25,000

  2022 · CANCER RESEARCH

Where these grants went next →

Grants received

• AMERICAN ENDOWMENT FOUNDATION

  $80,000

  2024 · HEALTH, GENERAL

• AMERICAN ENDOWMENT FOUNDATION

  $75,000

  2023 · HEALTH, GENERAL

• THE DALLAS FOUNDATION

  $60,000

  2024 · GENERAL SUPPORT

• THE DALLAS FOUNDATION

  $50,000

  2023 · GENERAL SUPPORT

• AMERICAN ENDOWMENT FOUNDATION

  $50,000

  2022 · HEALTH, GENERAL

• FIDELITY INVESTMENTS CHARITABLE GIFT FUND

  $32,400

  2024 · For grant recipient's exempt purposes

• FIDELITY INVESTMENTS CHARITABLE GIFT FUND

  $26,100

  2023 · For grant recipient's exempt purposes

• FIDELITY INVESTMENTS CHARITABLE GIFT FUND

  $25,000

  2022 · For grant recipient's exempt purposes

• GREATER HORIZONS

  $25,000

  2024 · Health, Medicine & Science

• DONOR ADVISED CHARITABLE GIVING

  $14,180

  2024 · PUBLIC, SOCIETAL BENEFIT

The 10 largest by cash amount. The API serves every itemized grant.

Other IRS files